SIGA Technologies/$SIGA
1D1W1MYTD1Y5YMAX
About SIGA Technologies
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
- Ticker
- $SIGA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 49
- Headquarters
- New York, United States
- Website
- www.siga.com
SIGA Metrics
BasicAdvanced
$232M
-
-$0.04
0.89
$0.60
18.58%
Price and volume
Market cap
$232M
Beta
0.89
52-week high
$9.45
52-week low
$2.83
Average daily volume
823K
Dividend rate
$0.60
Financial strength
Current ratio
21.717
Quick ratio
15.902
Total debt to equity
0.266
Profitability
EBITDA (TTM)
-10.547
Gross margin (TTM)
16.28%
Net profit margin (TTM)
-5.19%
Operating margin (TTM)
-20.76%
Effective tax rate (TTM)
49.44%
Revenue per employee (TTM)
$1,100,000
Management effectiveness
Return on assets (TTM)
-3.39%
Return on equity (TTM)
-1.49%
Valuation
Price to revenue (TTM)
4.313
Price to book
1.4
Price to tangible book (TTM)
1.41
Price to free cash flow (TTM)
-11.293
Free cash flow yield (TTM)
-8.86%
Free cash flow per share (TTM)
-0.286
Dividend yield (TTM)
18.58%
Growth
Revenue change (TTM)
-70.13%
Earnings per share change (TTM)
-103.41%
3-year revenue growth (CAGR)
-18.13%
10-year revenue growth (CAGR)
19.97%
3-year earnings per share growth (CAGR)
-53.76%
10-year earnings per share growth (CAGR)
-26.50%
What the Analysts think about SIGA
Analyst ratings (Buy, Hold, Sell) for SIGA Technologies stock.
SIGA Financial Performance
Revenues and expenses
SIGA Earnings Performance
Company profitability
SIGA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.